Journal
Journal of Clinical Oncology
Publication Date
1-20-2025
Volume
43
Issue
3
First Page
318
Last Page
328
Document Type
Open Access Publication
DOI
10.1200/JCO.23.02470
Rights and Permissions
Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trněný M, Bartlett NL, Zaucha J, Wrobel T, Offner F, Humphrey K, Relf J, Filézac de L'Etang A, Carlile DJ, Byrne B, Qayum N, Lundberg L, Dickinson M. Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. J Clin Oncol. 2025 Jan 20;43(3):318-328. doi: 10.1200/JCO.23.02470. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Phillips, Tycel Jovelle; Bartlett, Nancy L; and et al., "Glofitamab in relapsed/refractory mantle cell lymphoma: Results from a phase I/II study." Journal of Clinical Oncology. 43, 3. 318 - 328. (2025).
https://digitalcommons.wustl.edu/oa_4/4683
Additional Links
Supplemental material is available for this article at publisher site.
